Feasibility of tissue re-biopsy in non-small cell lung cancers resistant to previous epidermal growth factor receptor tyrosine kinase inhibitor therapies

BACKGROUND: When epidermal growth factor receptor (EGFR) gene mutation-positive non-small cell lung cancer (NSCLC) acquires resistance to the initial tyrosine kinase inhibitor (TKI) treatment, reassessing the tumor DNA by re-biopsy is essential for further treatment selection. However, the process o...

Descripción completa

Detalles Bibliográficos
Autores principales: Uozu, Sakurako, Imaizumi, Kazuyoshi, Yamaguchi, Teppei, Goto, Yasuhiro, Kawada, Kenji, Minezawa, Tomoyuki, Okamura, Takuya, Akao, Ken, Hayashi, Masamichi, Isogai, Sumito, Okazawa, Mitsushi, Hashimoto, Naozumi, Hasegawa, Yoshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719748/
https://www.ncbi.nlm.nih.gov/pubmed/29212495
http://dx.doi.org/10.1186/s12890-017-0514-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719748/
https://www.ncbi.nlm.nih.gov/pubmed/29212495
http://dx.doi.org/10.1186/s12890-017-0514-3

Ejemplares similares